NasdaqGM - Delayed Quote • USD
Theravance Biopharma, Inc. (TBPH)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:17 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.25 | -0.21 | -0.68 | -0.4 |
| Low Estimate | -0.4 | -0.28 | -0.96 | -0.75 |
| High Estimate | -0.16 | -0.18 | -0.3 | 0.32 |
| Year Ago EPS | -0.35 | -0.28 | -1 | -0.68 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 13.96M | 15.6M | 71.1M | 83.2M |
| Low Estimate | 11.1M | 14.7M | 61.4M | 73.7M |
| High Estimate | 15.75M | 17.18M | 87.5M | 96.55M |
| Year Ago Sales | 13.84M | 13.75M | 57.42M | 71.1M |
| Sales Growth (year/est) | 0.90% | 13.50% | 23.80% | 17.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.26 | -0.21 | -0.21 | -0.15 |
| EPS Actual | -0.35 | -0.28 | -0.17 | -0.17 |
| Difference | -0.09 | -0.07 | 0.04 | -0.02 |
| Surprise % | -34.60% | -33.30% | 19.00% | -13.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.25 | -0.21 | -0.68 | -0.4 |
| 7 Days Ago | -0.25 | -0.22 | -0.64 | -0.32 |
| 30 Days Ago | -0.25 | -0.22 | -0.64 | -0.32 |
| 60 Days Ago | -0.25 | -0.23 | -0.61 | -0.2 |
| 90 Days Ago | -0.25 | -0.23 | -0.61 | -0.2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TBPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 28.60% | -- | -- | 1.60% |
| Next Qtr. | 25.00% | -- | -- | 10.50% |
| Current Year | 32.00% | -- | -- | 5.20% |
| Next Year | 41.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 54.10% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | BTIG: Buy | 4/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
| Maintains | HC Wainwright & Co.: Buy | 5/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 2/28/2023 |
| Maintains | SVB Leerink: Outperform | 11/17/2022 |
| Maintains | HC Wainwright & Co.: Buy | 11/8/2022 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.41
+0.60%
TIL Instil Bio, Inc.
10.64
+3.30%
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
NXTC NextCure, Inc.
1.6000
+1.91%
PMVP PMV Pharmaceuticals, Inc.
1.6100
-0.62%
ANAB AnaptysBio, Inc.
19.87
+0.20%
CLRB Cellectar Biosciences, Inc.
3.0300
-0.33%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.3900
+9.13%
SPRO Spero Therapeutics, Inc.
1.4000
-4.76%
QTTB Q32 Bio Inc.
22.49
-7.75%